Oncology

Nivolumab plus ipilimumab is the first immunotherapy approved for previously untreated unresectable malignant pleural mesothelioma.

The results of an additional secondary endpoint from the phase 3 HERO study evaluating oral relugolix in men with advanced prostate cancer showed that relugolix had a similar rate of castration resistance-free survival compared to intravenous leuprolide acetate in men with metastatic disease through 48 weeks.

Using a 3D model, investigators found a soy-based compound was effective in treating bone cancer.

At ESMO 2020, researchers discussed some long-awaited data regarding postoperative radiotherapy used in patients with non-small cell lung cancer following complete resection and after (neo) adjuvant chemotherapy.

New drug application been submitted for TLX591-CDx (illumet), a radiopharmaceutical product that targets prostate-specific membrane antigen for the imaging of prostate cancer.

Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.

The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.

Study shows that upon hospital admission for cancer, many patients already have a high prevalence of malnutrition per Global Leadership Initiative on Malnutrition criteria.

The results from a cohort of patients with rare sarcomas in the phase 2 study, presented by professor Jean-Yves Blay, MD, investigated the efficacy and safety of single agent pembrolizumab in rare cancers.

A new study showed that nivolumab was effective in patients with pathogenic exonuclease domain POLE mutated mismatch repair.

The effects of pralsentinib were especially pronounced in treatment-naïve patients with medullary thyroid cancer.

The predictive value provided by T effector and angiogenesis signatures were found to be augmented by Kidney Immune Classification of tumor microenvironments.

Although immune checkpoint inhibitors are not yet approved for first-line therapy in these populations, the new research could lead to a new standard of care.

Adding atezolizumab (Tecentriq) to bevacizumab (Avastin) and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

More than half of high-risk patients with resected, stage III BRAF V600-mutated melanoma who were treated with dabrafenib and trametinib were alive and relapse-free at 5 years.

The COVID-19 pandemic will be felt in the oncology space long after the pandemic is over, study shows.

The CheckMate 9ER trial took 2 drugs used as monotherapies in the second line of therapy, nivolumab and cabozantinib, and combined them for use as a first-line treatment against standard of care, sunitinib.

More targeted therapies often have better toxicity profiles, allowing patients to remain adherent for longer.

Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) showed early antitumor activity and tolerability in previously treated triple-negative breast cancer patients with advanced solid tumors.

Trial shows that olaparib, a poly ADP ribose polymerase inhibitor that is the first cancer drug to target an inherited genetic fault, can be used successfully to treat prostate cancers with a weakness in the ability to repair damaged DNA.

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

Clinical education, strong data analytics, and valuing collaboration are the best ways to provide patient support and access to specialty pharmaceutical manufacturers.

Study shows the recurrence rate was within the expected range for breast cancer survivors receiving spironolactone and those who did not.

The COVID-19 pandemic has contributed to specialty pharmacy outpacing traditional pharmacy in non-discounted spending.

A new test may help direct treatments for patients with rare breast cancer mutations.

The CINtec PLUS Cytology assay is indicated for women who undergo cervical cancer screening and test positive for high-risk types of human papillomavirus.

Because regular SMS messaging is not fully HIPAA-compliant, one solution may be to initiate contact via a text that links to an online platform.

The keynote presentation will be broadcast virtually on 4 dates this fall and highlight cancer-specific guidance for pharmacists during the COVID-19 pandemic.

Buffalo Bills Hall of Fame quarterback Jim Kelly shared with specialty pharmacists his story of perseverance, tincluding his fight against squamous cell carcinoma in his upper jaw.

Magrolimab is a first-in-class, investigational anti-CD47 monoclonal antibody used in combination with azacitidine in treatment-naïve patients with high and very high-risk myelodysplastic syndrome,